Estrigenix Therapeutics Funding Round

7/21/2026

Venture Equity

$2,000,000

Seed

The company intends to use the funds to support lead optimization and completion of the its translational preclinical package, positioning its lead programs for IND-enabling studies and future clinical development.

Private & Independent

Biopharmaceutical

1225 Discovery Pkwy 255C
Wauwatosa, WI 53226
USA

Undisclosed

Not Recorded

Estrigenix Therapeutics, Inc. was formed in 2018 to develop and commercialize first-in-class therapeutics to treat and prevent hot flashes and dementia in post-menopausal women. Estrigenix is a privately held pharmaceutical company leading the way in research and progress in estrogen biology. We are working on a family of compounds to specifically help women by addressing the symptoms of menopause, moderating hot flashes and improving memory without the risks of breast cancer and stroke associated with traditional hormone replacement therapy. Because there is a correlation between the severity of a hot flashes in women in their 50s with an increased risk of developing dementia in their 60s and beyond, safe treatment for hot flashes may prevent the symptoms of Alzheimer's disease from developing. Our mission is to develop drugs, based on our platform technology and expertise in estrogen biology, that can help women live healthier and longer lives.